IDYA — IDEAYA Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1676725 ·
Last close
$27.40
Market Cap
$2.65B
52W High
$42.68
52W Low
$26.69
ADV30
1,011,309
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,242,000 | — | -137,632,000 | -125,749,000 | 1,216,020,000 | 261,452,000 | 123,957,000 |
| Jun 2026 | 8,857,000 | — | -122,291,000 | -112,452,000 | 1,309,699,000 | 272,589,000 | 110,794,000 |
| Mar 2026 | 6,560,000 | — | -108,544,000 | -98,539,000 | 1,030,348,000 | 157,522,000 | 93,081,000 |
| Dec 2025 | 10,876,000 | — | -94,570,000 | -83,273,000 | 1,109,324,000 | 112,825,000 | 86,390,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-347,358,000
Investing CF
$-55,857,000
Financing CF
$366,216,000
CapEx
$-2,439,000
Dividends Paid
—
Buybacks
$-9,000
EPS Diluted TTM
$-4.49
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,073,279,000
Inventory
—
Receivables
$10,242,000
ST Investments
$577,089,000
EBIT TTM
$-463,037,000
Pretax Income TTM
$-420,013,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,536,000
EBITDA
$-460,324,992
Free Cash Flow
$-214,216,496
Enterprise Value
$2,211,900,416
Total Cash
$838,540,992
Total Debt
$29,703,000
Shares Out
96,694,575
Trailing EPS
$-4.50
Book Value
$11.30
ROE
-38.5%
ROA
-24.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 218,710,000 | -159,313,000 | -113,698,000 | 1,109,324,000 | 86,390,000 | 1,022,934,000 | -71,098,000 |
| Dec 2024 | 7,000,000 | -326,975,000 | -274,477,000 | 1,124,091,000 | 64,944,000 | 1,059,147,000 | -247,584,000 |
| Dec 2023 | 23,385,000 | -134,429,000 | -112,961,000 | 649,316,000 | 28,226,000 | 621,090,000 | -115,224,000 |
| Dec 2022 | 50,931,000 | -62,502,000 | -58,655,000 | 387,969,000 | 38,514,000 | 349,455,000 | -87,175,000 |
TTM Snapshot
Revenues TTM
$234,127,000
NetIncome TTM
$-175,020,000
OpCashFlow TTM
—
Assets (Latest)
$1,309,699,000
Forward EPS
$-4.15
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $32.50 · spot: $26.49 · call volume: 280 · put volume: 108Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | $2.64B | $53.10 | — |
| XNCR | Xencor Inc | $2.59B | $34.50 | — |
| HCM | HUTCHMED (China) Ltd | $2.50B | $14.40 | — |
| ZLAB | Zai Lab Ltd | $2.91B | $23.53 | — |
| RCUS | Arcus Biosciences, Inc. | $2.36B | $16.39 | — |
News headlines (Yahoo Finance, 1h cache)
Is IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?
2026-11-18 01:12 · Yahoo
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TO
2026-11-16 21:05 · Yahoo
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
2026-11-15 20:00 · Yahoo
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
2026-11-04 11:00 · Yahoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
2026-11-03 11:25 · Yahoo
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
2026-11-03 11:00 · Yahoo
Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?
2026-10-31 05:13 · Yahoo
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 10:00 · Yahoo
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-10-27 13:00 · Yahoo
IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow
2026-10-08 17:18 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.